company background image
SPAR

Sun Pharma Advanced ResearchNSEI:SPARC Stock Report

Last Price

₹322.15

Market Cap

₹84.9b

7D

3.0%

1Y

77.2%

Updated

22 Jan, 2022

Data

Company Financials
SPARC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

SPARC Stock Overview

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Sun Pharma Advanced Research
Historical stock prices
Current Share Price₹322.15
52 Week High₹337.85
52 Week Low₹141.00
Beta1.01
1 Month Change28.19%
3 Month Change13.15%
1 Year Change77.15%
3 Year Change91.81%
5 Year Change0.093%
Change since IPO269.44%

Recent News & Updates

Nov 23
Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?

Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

SPARCIN PharmaceuticalsIN Market
7D3.0%-4.5%-3.4%
1Y77.2%8.8%32.6%

Return vs Industry: SPARC exceeded the Indian Pharmaceuticals industry which returned 8.8% over the past year.

Return vs Market: SPARC exceeded the Indian Market which returned 32.6% over the past year.

Price Volatility

Is SPARC's price volatile compared to industry and market?
SPARC volatility
SPARC Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.8%
10% most volatile stocks in IN Market9.9%
10% least volatile stocks in IN Market4.0%

Stable Share Price: SPARC is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SPARC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006410Anilkumar Raghavanhttps://www.sparc.life

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension.

Sun Pharma Advanced Research Fundamentals Summary

How do Sun Pharma Advanced Research's earnings and revenue compare to its market cap?
SPARC fundamental statistics
Market Cap₹84.86b
Earnings (TTM)-₹2.41b
Revenue (TTM)₹997.27m

85.1x

P/S Ratio

-35.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SPARC income statement (TTM)
Revenue₹997.27m
Cost of Revenue₹246.79m
Gross Profit₹750.48m
Expenses₹3.16b
Earnings-₹2.41b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-9.14
Gross Margin75.25%
Net Profit Margin-241.51%
Debt/Equity Ratio3,178.0%

How did SPARC perform over the long term?

See historical performance and comparison

Valuation

Is Sun Pharma Advanced Research undervalued compared to its fair value and its price relative to the market?

1798.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SPARC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SPARC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SPARC is unprofitable, so we can't compare its PE Ratio to the Indian Pharmaceuticals industry average.

PE vs Market: SPARC is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SPARC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SPARC is overvalued based on its PB Ratio (1798x) compared to the IN Pharmaceuticals industry average (3.2x).


Future Growth

How is Sun Pharma Advanced Research forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sun Pharma Advanced Research has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Sun Pharma Advanced Research performed over the past 5 years?

-10.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SPARC is currently unprofitable.

Growing Profit Margin: SPARC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SPARC is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.

Accelerating Growth: Unable to compare SPARC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPARC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (29.7%).


Return on Equity

High ROE: SPARC has a negative Return on Equity (-5102.73%), as it is currently unprofitable.


Financial Health

How is Sun Pharma Advanced Research's financial position?


Financial Position Analysis

Short Term Liabilities: SPARC's short term assets (₹1.4B) do not cover its short term liabilities (₹2.0B).

Long Term Liabilities: SPARC's short term assets (₹1.4B) exceed its long term liabilities (₹882.8M).


Debt to Equity History and Analysis

Debt Level: SPARC's net debt to equity ratio (1419.7%) is considered high.

Reducing Debt: SPARC's debt to equity ratio has increased from 0.9% to 3178% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SPARC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SPARC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.7% each year


Dividend

What is Sun Pharma Advanced Research current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SPARC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SPARC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SPARC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SPARC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SPARC's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Anilkumar Raghavan (52 yo)

7.75yrs

Tenure

Mr. Anilkumar Raghavan has been the Chief Executive Officer of Sun Pharma Advanced Research Company Limited since April 24, 2014. Mr. Raghavan is a senior pharmaceutical services executive with significant...


Leadership Team

Experienced Management: SPARC's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: SPARC's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sun Pharma Advanced Research Company Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Sun Pharma Advanced Research Company Limited
  • Ticker: SPARC
  • Exchange: NSEI
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹84.864b
  • Shares outstanding: 263.43m
  • Website: https://www.sparc.life

Number of Employees


Location

  • Sun Pharma Advanced Research Company Limited
  • 17-B, Mahal Industrial Estate
  • Off Mahakali Caves Road
  • Mumbai
  • Maharashtra
  • 400093
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/22 12:05
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.